Summary:
Shilpa Medicare shares rose 5% after its subsidiary signed a co-development and exclusive supply agreement with Orion Pharma for a nivolumab biosimilar in Europe. Under the deal, Shilpa will develop, manufacture, and supply the product, while Orion will handle commercialization across Europe. The partnership is expected to generate milestone payments and long-term supply revenue for Shilpa Medicare.
The stocks of Shilpa Medicare gained 5% in opening trades on June 30, 2026, due to the announcement of an important international collaboration. The stocks were trading at ₹601.45 as of 10:45 AM, registering a rise of 5%. The highest point reached by the stocks during the trading session was ₹605.50, while the lowest point touched was ₹576. The trading volume recorded was 1.05 lakh, which was below the average 30-day trading volume of 1.48 lakh.
Strategic Europe Biosimilar Agreement
This was following the formation of a co-development and exclusive supply arrangement between SBPL, a wholly owned company of Shilpa Medicare, and Orion Corporation. This agreement will be concentrated on the development of an intravenous nivolumab biosimilar for the European market.
Nivolumab is a PD-1 immunotherapy medication which is extensively used in oncological therapy for the treatment of melanoma and lung cancer. Based on IQVIA and IMS reports provided by the organizations, the drug created sales worth of approximately USD 4.1 billion in Europe during 2025.
Scope of Co-Development and Manufacturing Role
Under the terms of the agreement, Shilpa Biologicals will develop, produce and supply exclusively the nivolumab biosimilar product. The production process will be conducted by Shilpa Biologicals from its biological drugs manufacturing plant situated in Dharwad, India, that will allow integrated development and commercial production.
From the marketing point of view, exclusive rights for registration, marketing, distribution, and selling the nivolumab biosimilar will be provided to Orion Corporation in Europe.
Financial Structure and Revenue Visibility
Shilpa Medicare is set to be compensated through milestone payments from Orion as the project develops. Further on, Shilpa Medicare will also earn supply revenues as the product enters the commercial phase. Even though the exact figures have not been released yet, one can conclude that this revenue generation process may span several years.
Strategic Continuity and Existing Partnership
This collaboration draws on the previous ties between the two firms where Shilpa had provided recombinant human albumin for Europe. This deal on nivolumab biosimilar adds more to this partnership and brings it to a higher level in the field of immuno-oncology.
Management Commentary and Industry Outlook
According to Shilpa Medicare, the agreement is a landmark one because of the fact that it shows confidence in the ability of the company to manufacture advanced biologic products on an industrial scale. The management of Orion also pointed out that the agreement fits in with the company’s strategy regarding Europe.
Company Background and Outlook
Shilpa Medicare is a diversified pharma and biotech firm specializing in complex generics, biologics, and APIs. The company has an EU-GMP certified biologics platform in Dharwad through its subsidiary, SBPL.
Orion Corporation is a Nordic firm in the pharmaceutical industry that has more than a century-long existence. The firm is engaged in both pharmaceuticals and consumer health care, with oncology and pain management as their key focuses. Net sales of Orion for 2025 were EUR 1,890 million.
Conclusion
This agreement makes Shilpa Medicare a significant player in the manufacturing of European biosimilar nivolumab while Orion gains exclusive commercialization rights in an important sector of oncology. With milestone-based payments and commitments to long-term supplies, the agreement adds another dimension to the future of growth of Shilpa in biologics.
